Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

71.46 +1.58 (+2.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
Why AstraZeneca Stock Topped the Market on Tuesday
Via The Motley Fool
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
3 No-Brainer Stocks to Buy for Under $100 Right Now
Via The Motley Fool
Topics Intellectual Property
Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect.
President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy. 
Via Investor's Business Daily
Topics Government
Looking Into AstraZeneca's Recent Short Interest
Via Benzinga
DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
From AstraZeneca
Via Business Wire
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due. 
Via Benzinga
Is the Market Bullish or Bearish on AstraZeneca?
Via Benzinga
AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion
AstraZeneca inks a multibillion-dollar deal with CSPC to co-develop AI-driven therapies for chronic and immune diseases, boosting its presence in China. 
Via Benzinga
AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer
CSPC will receive an upfront payment of $110 million as part of the agreement, and is eligible to receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales... 
Via Stocktwits
Topics Artificial Intelligence
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA
IonQ just hit investors with two pieces of big news. One shows proof of the company's tech being useful near-term. The other looks to aid its long-term goals. 
Via MarketBeat
Jensen Huang's Quantum Support Boosts IonQ's Growth Plans: Nvidia Partnership, Oxford Ionics Deal Lead Needham To Reiterate 'Buy'
Needham maintained its 'buy' rating on IonQ, saying that the Oxford Ionics acquisition could propel 2 million physical qubits by 2030. 
Via Benzinga
What's Going On With IonQ Shares Monday?
IonQ shares traded higher Monday after the company announced results of a collaborative research program with AstraZeneca, Amazon Web Services and Nvidia. 
Via Benzinga
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season
Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color. 
Via Benzinga
Is D-Wave Quantum a Better Quantum Computing Stock to Buy Than IonQ?
Via The Motley Fool
AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO
AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ASCO 2025. 
Via Benzinga
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
Three new cancer drugs could help make a dent in the company's ambitious plans for 2030. 
Via Investor's Business Daily
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
From AstraZeneca
Via Business Wire
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
From AstraZeneca
Via Business Wire
Why Tempus AI Stock Plummeted This Week
Via The Motley Fool
Topics Artificial Intelligence
Why Artificial Intelligence Stock Tempus AI Is Tumbling Today
An investment management firm known for short-selling the stocks it speaks against is now targeting a high-risk, high-reward stock purchased by a high-profile politician. 
Via The Motley Fool
Topics Artificial Intelligence
The Promise of Quantum Computing
The race to quantum supremacy is on. While this future will not come tomorrow, big tech companies are building to the technology's "ChatGPT moment." 
Via The Motley Fool
Topics Artificial Intelligence
AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
From AstraZeneca
Via Business Wire
3 Promising Growth Stocks You Can Buy for Less Than $100
Via The Motley Fool
How Does D-Wave Stack Up Against Quantum Competitors?
D-Wave, IonQ, and Rigetti are three of the most talked-about quantum computing firms; how do these three companies stack up against one another? 
Via MarketBeat
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
From AstraZeneca
Via Business Wire
George Soros Loads Up On First Solar Calls: What Does He Know That Wall Street Doesn't?
Soros Fund Management, in a surprise move, revealed a bold new bet on First Solar Inc., scooping up 1.6 million call options. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.